The co-deletion of BRCA2 and RB1 emerged as an independent genomic driver of castration-resistant prostate cancer (CRPC), contributing to an aggressive phenotype characterized by epithelial-to-mesenchymal transition (EMT). The gene discussed is BRCA2; the disease is prostate cancer.